Alzamend Neuro (ALZN) Projected to Post Earnings on Monday

Alzamend Neuro (NASDAQ:ALZN) is projected to issue its results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Tuesday, December 9th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.53. On average, analysts expect Alzamend Neuro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alzamend Neuro Trading Up 1.5%

Shares of ALZN opened at $1.98 on Friday. The firm’s 50-day moving average price is $2.06 and its 200-day moving average price is $2.23. Alzamend Neuro has a 1-year low of $1.58 and a 1-year high of $10.17. The firm has a market capitalization of $7.52 million, a price-to-earnings ratio of -0.60 and a beta of -0.25.

Analysts Set New Price Targets

A number of equities analysts have commented on ALZN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Alzamend Neuro in a research note on Monday, December 29th. Ascendiant Capital Markets reduced their price objective on Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.00.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. DRW Securities LLC raised its holdings in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 116,319 shares of the company’s stock after purchasing an additional 25,074 shares during the quarter. DRW Securities LLC owned 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.